See the DrugPatentWatch profile for eliquis
Eliquis, also known by its generic name apixaban, is prescribed for patients with atrial fibrillation (AFib) to prevent strokes and blood clots [1].
How does Eliquis work for AFib?
Eliquis is a direct oral anticoagulant (DOAC) that works by inhibiting Factor Xa, a protein crucial for blood clot formation [2]. By blocking Factor Xa, Eliquis reduces the ability of blood to clot, thereby lowering the risk of stroke in individuals with AFib [2][3].
When is Eliquis prescribed for AFib?
Eliquis is indicated for patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism [1]. It is a common treatment choice for many individuals diagnosed with this heart rhythm disorder [3].
What is the difference between Eliquis and other AFib medications?
Eliquis belongs to a class of anticoagulants called direct oral anticoagulants (DOACs), which also includes rivaroxaban (Xarelto) and dabigatran (Pradaxa) [3]. These DOACs are generally considered alternatives to warfarin (Coumadin), an older type of anticoagulant [3]. While warfarin requires frequent monitoring of blood clotting levels, DOACs like Eliquis typically do not require routine blood tests for dose adjustment [2][3].
When does Eliquis patent expire?
The primary patent for apixaban (Eliquis) is set to expire in 2026 in the United States [4]. However, additional patents related to its manufacturing and formulation may extend market exclusivity beyond this date [4]. Information on patent expiry dates for specific drugs can be found on DrugPatentWatch.com [4].
Can generic versions of Eliquis be used for AFib?
Once the relevant patents expire, generic versions of apixaban may become available. These generic versions would be expected to offer a more affordable alternative for patients with AFib [4].
What are the risks of taking Eliquis for AFib?
The most significant risk associated with Eliquis, like all anticoagulants, is bleeding [2]. Patients taking Eliquis may experience bleeding more easily, and any bleeding that occurs may take longer to stop [2][3]. It is important for patients to discuss any signs of bleeding, such as unusually heavy bruising, nosebleeds, or blood in urine or stool, with their healthcare provider immediately [2].
What clinical data supports Eliquis for AFib?
Clinical trials have demonstrated Eliquis's efficacy in reducing the risk of stroke and systemic embolism in patients with non-valvular AFib [1]. The ARISTOTLE trial, a landmark study, showed that apixaban was associated with significantly lower rates of stroke and systemic embolism compared to warfarin, with a similar rate of major bleeding and a lower rate of fatal bleeding [2].
What are patient concerns about Eliquis?
Patients often have questions regarding the cost of Eliquis, the management of bleeding risks, and potential interactions with other medications [2][3]. Discussions with healthcare providers typically cover these concerns, including what to do in case of missed doses or if surgery is required [2].
Sources:
[1] https://www.eliquis.com/
[2] https://www.drugpatentwatch.com/drug/apixaban/
[3] https://www.nhs.uk/medicines/apixaban/
[4] https://www.drugpatentwatch.com/